Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ju Sun Kim
The Impact of Cetuximab Plus AKT- Or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model With Wild-Type RAS and PIK3CA Mutation
Journal of Cancer
Oncology
Related publications
Antitumor Activity of Sorafenib Plus CDK4/6 Inhibitor in Pancreatic Patient Derived Cell With KRAS Mutation
Journal of Cancer
Oncology
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- And PIK3CA- Wild-Type Metastatic Colorectal Cancer: The AGITG Randomised Phase II ICECREAM Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
Control of the MYC-eIF4E Axis Plus mTOR Inhibitor Treatment in Small Cell Lung Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer
JAMA Oncology
Cancer Research
Oncology
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-Line Cetuximab and Irinotecan
JAMA Oncology
Cancer Research
Oncology
Mutant and Wild-Type Ras: Co-Conspirators in Cancer
Cancer Discovery
Oncology
FOLFIRI Plus Panitumumab in the Treatment of Wild-Type KRAS and Wild-Type NRAS Metastatic Colorectal Cancer
World Journal of Surgical Oncology
Surgery
Oncology
P16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients With Metastatic Colorectal Cancer
Cancer Research and Treatment
Cancer Research
Oncology
